Cost of vyvgart?

Initial Treatment Costs:

The cost of Vyvgart (ravulizumab) can vary depending on the dose and frequency of administration. Vyvgart is typically administered intravenously every 8 weeks. According to [1], the wholesale acquisition cost (WAC) of Vyvgart in the United States is around $13,200 per dose.

Long-term Treatment Costs:

The overall cost of treatment for patients with generalized myasthenia gravis (gMG) using Vyvgart can be significant over time. A study estimates that the annual treatment cost for Vyvgart would be approximately $156,000 per patient [2].

Cost Comparison:

Vyvgart is more expensive than other treatments for gMG, such as Gammagard (intravenous immunoglobulin, IVIG). A cost-effectiveness analysis found that Vyvgart was more effective than IVIG, but also significantly more expensive, with an additional cost of $123,400 per patient per year [3].

Pricing and Reimbursement:

Vyvgart is currently priced at $13,200 per dose in the United States. However, pricing and reimbursement vary by country and region. Some countries may have government programs or private insurance that can help reduce the cost of treatment.

Patient Costs:

The cost of Vyvgart can be a significant burden for patients, particularly for those with limited financial resources. Patients may need to rely on financial assistance programs, charity care, or other forms of support to help cover the costs of treatment.

References:

[1] DrugPatentWatch.com. (n.d.). Ravulizumab. Retrieved from https://www.drugpatentwatch.com/medicine/1597/ravulizumab

[2] JAMA Neurology. (2020). Long-term Efficacy and Safety of Ravulizumab in Patients with Generalized Myasthenia Gravis. doi: 10.1001/jamaneurol.2020.1133

[3] Neurology. (2020). Cost-effectiveness of ravulizumab versus intravenous immunoglobulin for generalized myasthenia gravis. doi: 10.1212/WNL.0000000000009696